eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 06/01/2011
SPC Anthisan Bite & Sting Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Anthisan Bite and Sting 2% w/w Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Mepyramine Maleate 2% w/w

Also contains:

 

Castor oil

23,60% w/w

Ceto-stearyl alcohol

13,80% w/w

Propylene glycol 600 monostearate

4,90% w/w

Methyl hydroxybenzoate

0,20% w/w

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

A smooth off-white cream


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic relief of skin irritation caused by insect stings, insect bites and nettle stings.

Route of Administration: Topical


Go to top of the page
4.2 Posology and method of administration

Adults, elderly and children over 2 years of age and older. Anthisan Bite and Sting Cream should be applied directly to the affected parts two or three times a day for up to three days. Early application is essential to obtain the optimum response.


Go to top of the page
4.3 Contraindications

Anthisan Bite and Sting Cream should not be used in eczematous conditions or on extensively broken skin surfaces, or if the skin is cut or grazed. Do not use on large areas of skin or on areas of sunburnt skin.

Hypersensitivity to the active substance or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Repeated application of Anthisan Bite and Sting Cream to the same area for longer than three days is not recommended and treatment should be discontinued immediately if skin sensitisation occurs.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No significant interactions described.


Go to top of the page
4.6 Pregnancy and lactation

There is no evidence of the safety of mepyramine maleate in human pregnancy, but it has been widely used for many years without apparent ill consequence. Absorption of a significant amount after topical application is unlikely in the prescribed method of use, nevertheless, Anthisan Bite and Sting Cream should not be used during pregnancy or lactation, unless considered essential.


Go to top of the page
4.7 Effects on ability to drive and use machines

Anthisan Bite and Sting Cream has minor or moderate influence on the ability to drive and use machines.

May theoretically be extensively absorbed through the skin when applied over large areas and cause somnolence and mild disorientation.


Go to top of the page
4.8 Undesirable effects

Skin sensitisation has been reported on rare occasions.


Go to top of the page
4.9 Overdose

A 20g tube of Anthisan Bite and Sting Cream contains 400mg mepyramine maleate. If accidentally ingested this dose would constitute a dangerous overdose in young children.

The chief symptoms of overdosage is unconsciousness and there may be convulsions in the intervening periods. The stomach should be washed out. Stimuli liable to provoke convulsions should be avoided, but if this complication should occur, parenteral Diazepam should be given, sedatives which are liable to increase respiratory depression should be avoided. Other measures such as artificial respiration and oxygen may also be required and an antibiotic can be given as a prophylactic against pneumonia.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Mepyramine maleate is an antihistamine with anti-pruritic and local analgesic actions.


Go to top of the page
5.2 Pharmacokinetic properties

No pharmacokinetic data available by any route of administration.


Go to top of the page
5.3 Preclinical safety data

There are no findings of relevance to the prescriber, additional to those already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Ceto-stearyl alcohol

Polyethylene glycol 600 monostearate

Castor oil

Methyl hydroxybenzoate

Foin coupe (fragrance)

Silicone antifoam

Purified water


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Store below 30°C


Go to top of the page
6.5 Nature and contents of container

Collapsible aluminium tube with extended nozzle and polyethylene screw cap containing 20g cream.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Sanofi-aventis

One Onslow Street

Guildford

Surrey, GU1 4YS, UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0275


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

September 2005


Go to top of the page
10. DATE OF REVISION OF THE TEXT

18 November 2010


Go to top of the page
LEGAL CATEGORY

GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/9266/SPC/


Active Ingredients/Generics

 
   mepyramine maleate